BRSK2 and cancer: LinJ.05.0350 protein, which has already been related to drug-resistant phenotype, was identified in our approach due to its similarity with Serine / threonine-protein kinase MRCK alpha (Q5VT25) and BRSK2 (Q8IWQ3), thus being inferred as a potential target for 28 compounds, including kinase inhibitors used as cancer treatment staurosporine and sunitinib, both compounds already described in the literature as potential anti-leishmanial (Dalton et al., 2010; Foucher et al., 2013; Sanderson et al., 2014; Balanco et al., 2019).